Patient-reported outcomes from a multicenter, randomized, vehicle-controlled clinical study of MAS063DP (Atopiclair) in the management of mild-to-moderate atopic dermatitis in adults

The Journal of Dermatological Treatment
William AbramovitsTerry M Jones

Abstract

MAS063DP (Atopiclair) is a topical cream approved for symptomatic relief in the treatment of atopic and contact dermatitis. This was a multicenter, randomized, double-blind, vehicle-controlled study in adults with mild-moderate atopic dermatitis. Patients were given MAS063DP or vehicle (2:1) three times per day to areas affected by atopic dermatitis for up to 50 days. A patient global assessment change from baseline was determined at days 8, 22, 36, and 50. Patient total body pruritus (visual analog scale) and patient opinion on treatment acceptability were also assessed. A total of 218 patients (active: n = 145, vehicle: n = 73) were enrolled. At Day 22, 77% of patients on MAS063DP had a patient global assessment of good improvement or better versus 21% on vehicle (p<0.0001, chi-squared test). Similarly, more patients had improvement in itch over their total body on MAS063DP than on vehicle (p<0.0001). MAS063DP treatment results in patient-perceived improvements in mild-moderate atopic dermatitis.

References

Jun 1, 1990·The Journal of Clinical Endocrinology and Metabolism·M A MacKenzieP W Kloppenborg
Jul 1, 1996·International Archives of Allergy and Immunology·Y M LeeH M Kim
May 1, 1996·The Australasian Journal of Dermatology·G Fischer
Jan 1, 1997·Immunology·B H KroesR P Labadie
Feb 1, 1997·Archives of Disease in Childhood·J C SuT M Nolan
Sep 14, 1999·The Journal of Allergy and Clinical Immunology·A B Fleischer
Jan 15, 2000·The Journal of Dermatology·C F Wahlgren
May 16, 2000·The British Journal of Dermatology·C R CharmanH C Williams
Jan 6, 2001·Journal of the American Academy of Dermatology·S J Tofte, J M Hanifin
Jan 6, 2001·Journal of the American Academy of Dermatology·S KangJ M Hanifin
Nov 13, 2001·American Journal of Clinical Dermatology·D Abeck, K Strom
Apr 16, 2003·The British Journal of Dermatology·C EllisUNKNOWN ICCAD II Faculty
Jun 22, 2005·Journal of the American Academy of Dermatology·William Abramovits
Jun 22, 2005·Journal of the American Academy of Dermatology·William Abramovits
Jul 15, 2005·Skinmed·William Abramovits, Aditya K Gupta
Dec 31, 2005·Journal of the American Academy of Dermatology·Ulrich R HenggeMichael J Cork
Mar 1, 2006·Journal of the European Academy of Dermatology and Venereology : JEADV·E A HolmG B E Jemec
May 17, 2006·Archives of Dermatology·Abrar A Qureshi, Michael A Fischer
Jul 4, 2006·The Journal of Allergy and Clinical Immunology·Torsten ZuberbierJan C Simon
Mar 1, 2007·Planta medica·Yong-Wook ShinDong-Hyun Kim

❮ Previous
Next ❯

Citations

Oct 29, 2013·Clinics in Dermatology·Ronni Wolf, Lawrence Charles Parish
Aug 20, 2011·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Hans Christian Korting, Claudia Schöllmann
May 2, 2009·Expert Opinion on Pharmacotherapy·A PatriziI Neri
Feb 7, 2017·The Cochrane Database of Systematic Reviews·Esther J van ZuurenBernd WM Arents
Apr 23, 2017·The British Journal of Dermatology·E J van ZuurenB W M Arents
May 3, 2021·Journal of Cosmetic Dermatology·Mauro BarbareschiStefano Veraldi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.